D60.1
Transient acquired pure red cell aplasia
Clinical Classification Guidelines
Medical Intelligence & Overview
Transient acquired pure red cell aplasia is a rare blood disorder characterized by a temporary loss of red blood cell production in the bone marrow. This condition leads to a sudden decrease in red blood cells, resulting in anemia. Unlike some other types of anemia, pure red cell aplasia specifically affects only the red blood cell lineage, with other blood components remaining unaffected. The 'transient' nature indicates that the condition may resolve on its own or with treatment, but it can also recur or become chronic in some cases.
Causes & Symptoms
Clinical Causes: Autoimmune responses where the body's immune system mistakenly attacks red blood cell precursors Viral infections such as parvovirus B19, hepatitis B and C, or HIV Reaction to certain drugs, including some antibiotics, chemotherapy agents, or other medications Associations with thymomas or other thymic abnormalities Idiopathic cases where no specific cause can be identified
Key Symptoms: Sudden onset of severe anemia Fatigue and weakness Shortness of breath, especially during exertion Pale skin and mucous membranes Rapid heartbeat or palpitations Dizziness or lightheadedness Less common: fever or signs of underlying infections or immune activity
Diagnostic & Treatment
Diagnosis Path: Diagnosing transient acquired pure red cell aplasia involves blood tests that reveal a significant decrease in red blood cells, hemoglobin, and hematocrit, alongside normal white blood cell and platelet counts. Bone marrow examination is critical, typically showing a marked reduction or absence of red cell precursors while other lineages remain healthy. Additional tests to identify underlying causes include viral serologies, autoimmune panels, and imaging studies if a thymic abnormality is suspected.
Treatment Protocols: Corticosteroids to suppress immune responses that may be attacking red cell precursors Immunosuppressive therapy in cases linked to autoimmune mechanisms Treating underlying infections with appropriate antimicrobial agents Discontinuing offending drugs if they are suspected causes Supportive care such as blood transfusions to manage severe anemia Monitoring for recurrence or progression to chronic forms, with further interventions as needed
Clinical Advice & FAQs
Billing Guidance
Is D60.1 a billable ICD-10 code?
Yes, D60.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D60.1?
Clinical documentation must specify the nature of Transient acquired pure red cell aplasia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference